Li-gong Lu
Overview
Explore the profile of Li-gong Lu including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
37
Citations
730
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Zhao R, Liu D, Li J, Wang Y, Lin J, Zhang Y, et al.
J Leukoc Biol
. 2024 Apr;
116(1):186-196.
PMID: 38648512
Transarterial embolization, the first-line treatment for hepatocellular carcinoma, does not always lead to promising outcomes in all patients. A better understanding of how the immune lymphocyte changes after transarterial embolization...
2.
Lin F, Gao J, Xu Q, Wang G, Xiao L, Dong L, et al.
J Nat Prod
. 2024 Mar;
87(5):1338-1346.
PMID: 38447084
Oxabornyl polyenes represent a unique group of polyketides characterized by a central polyene core flanked by a conserved oxabornyl moiety and a structurally diverse oxygen heterocyclic ring. They are widely...
3.
Zhu H, Li X, Sun J, Zhu X, Liu Z, Li H, et al.
Cardiovasc Intervent Radiol
. 2024 Feb;
47(3):325-336.
PMID: 38413420
Purpose: While the role of drug-eluting beads transarterial chemoembolization (DEB-TACE) for hepatocellular carcinoma (HCC) is established, questions regarding appropriate bead size for use in patients remain. This trial evaluated the...
4.
Han X, Liu L, Fang X, Jiang S, Zhao H, Qian Z, et al.
J Nat Med
. 2023 Jul;
77(4):986-991.
PMID: 37515674
Chinese cordyceps, also known as Dong-Chong-Xia-Cao, is widely recognized as a famous precious tonic herb, and used as traditional Chinese medicine for centuries. It is mainly used for regulating the...
5.
Lu J, Guo J, Ji J, Li Y, Lv W, Zhu H, et al.
Int J Surg
. 2023 Apr;
109(5):1188-1198.
PMID: 37038986
Background And Aim: Treatment strategy for hepatocellular carcinoma (HCC) and Vp4 [main trunk] portal vein tumor thrombosis (PVTT) remains limited due to posttreatment liver failure. We aimed to assess the...
6.
Zhu H, Li H, Huang M, Yang W, Yin G, Zhong B, et al.
Signal Transduct Target Ther
. 2023 Feb;
8(1):58.
PMID: 36750721
There is considerable potential for integrating transarterial chemoembolization (TACE), programmed death-(ligand)1 (PD-[L]1) inhibitors, and molecular targeted treatments (MTT) in hepatocellular carcinoma (HCC). It is necessary to investigate the therapeutic efficacy...
7.
Liu B, He X, Wang Y, Huang J, Zheng Y, Li Y, et al.
Front Immunol
. 2022 May;
13:874640.
PMID: 35493488
γδ T cells are one of only three immune cell types that express antigen receptors that undergo somatic recombination, and they contribute to immune responses to infection, cellular transformation, and...
8.
Biodegradable PTX-PLGA-coated magnesium stent for benign esophageal stricture: An experimental study
Liu L, Qin J, Zeng C, Du R, Pan T, Ji J, et al.
Acta Biomater
. 2022 Apr;
146:495-505.
PMID: 35487426
Biodegradable stents can degrade step by step and thereby avoid secondary removal by endoscopic procedures in contrast to metal stents. Herein, a biodegradable composite stent, a magnesium (Mg)-based braided stent...
9.
Lu L, Zhou Z, Wang X, Liu B, Lu J, Liu S, et al.
Gut
. 2022 Feb;
71(12):2551-2560.
PMID: 35173040
Objective: Patients with increased PD-L1 host cells in tumours are more potent to benefit from antiprogrammed death-1/programmed death ligand-1 (PD-L1) treatment, but the underlying mechanism is still unclear. We aim...
10.
Wei J, Fu S, Zhang J, Gu D, Li X, Chen X, et al.
Hepatobiliary Pancreat Dis Int
. 2021 Oct;
21(4):325-333.
PMID: 34674948
Background: Macrovascular invasion (MaVI) occurs in nearly half of hepatocellular carcinoma (HCC) patients at diagnosis or during follow-up, which causes severe disease deterioration, and limits the possibility of surgical approaches....